Sign In
Buy AMLX
$13.20
-0.0900 (-0.677%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced that Week 24 and Week 48 results from the Phase 2 open-label HELIOS c
Amylyx Pharmaceuticals Eyes Phase 3 AVEXITIDE Readout as 2027 Launch Comes Into Focus
01:06am, Thursday, 14'th May 2026
Amylyx Pharmaceuticals NASDAQ: AMLX is preparing for a pivotal Phase 3 readout for AVEXITIDE, its lead asset for post-bariatric hypoglycemia, or PBH, with data from the LUCIDITY trial expected in the
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
08:20pm, Wednesday, 13'th May 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
05:01pm, Thursday, 07'th May 2026
Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
07:00am, Thursday, 07'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results.
Amylyx Pharmaceuticals Announces U.S. Expanded Access Program for Adults with Post-Bariatric Hypoglycemia
07:00am, Tuesday, 05'th May 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the launch of a U.S. Expanded Access Program (EAP) for up to 250 adul
Amylyx Pharmaceuticals Sets Up Q3 Phase 3 Avexitide Data Readout, Eyes Potential 2027 Launch
03:31am, Friday, 17'th Apr 2026
Amylyx Pharmaceuticals (NASDAQ: AMLX) is entering what it described as a pivotal year for its lead program, avexitide, with Phase 3 data expected in the third quarter and preparations underway for a p
Did Amylyx Pharmaceuticals, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
07:54pm, Thursday, 09'th Apr 2026
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible
Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
09:00am, Wednesday, 08'th Apr 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia.
437,391 Shares in Amylyx Pharmaceuticals, Inc. $AMLX Purchased by Ally Bridge Group NY LLC
03:31am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC acquired a new position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) in the undefined quarter, according to the company in its most recent filing with the Securities and Exc
Amylyx Pharmaceuticals, Inc. $AMLX Shares Acquired by Alpha Wave Global LP
03:05am, Saturday, 14'th Mar 2026
Alpha Wave Global LP increased its position in Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) by 18.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commi
Amylyx Pharmaceuticals Q4 Earnings Call Highlights
01:32am, Thursday, 05'th Mar 2026
Amylyx Pharmaceuticals (NASDAQ: AMLX) executives told investors the company entered 2026 with a focus on advancing avexitide toward what could become the first FDA-approved therapy for post-bariatric
Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
06:03pm, Wednesday, 04'th Mar 2026
Amylyx Pharmaceuticals (AMLX) is downgraded from 'Strong Buy' to 'Buy' following the discontinuation of AMX0035 for PSP. Company's investment thesis now centers on avexitide, a GLP-1 receptor antagoni
Amylyx Pharmaceuticals Says 2026 Could Be “Transformative” Ahead of Avexitide Phase 3 Readout
04:32am, Wednesday, 04'th Mar 2026
Amylyx Pharmaceuticals (NASDAQ: AMLX) executives outlined a slate of milestones they expect to shape the company's near-term trajectory during TD Cowen's 46th Annual Healthcare Conference, with co-CEO
